Ennature Bio Pharma Ltd
Ennature Bio Pharma Ltd (ENNATURE) last reported results for the quarter ended Sep 2026, with sales of ₹78.46 crore and net profit of ₹4.89 crore. The stock last traded at ₹189, a market capitalisation of ₹420 crore, on a P/E of 55.2. Over the past 52 weeks the stock has ranged between ₹189 and ₹275. Figures are as of 17 Nov 2026 and are not real time.
Ennature Bio Pharma Ltd share price and key metrics
- Current price
- ₹189
- Market cap
- ₹420 cr
- Stock P/E
- 55.2
- ROE
- %
- ROCE
- %
- Dividend yield
- 0.00%
- 52w high / low
- 275/189
Metrics as of 17 Nov 2026. Not real time.
Track Ennature Bio Pharma Ltd
Cruxal reads every Ennature Bio Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Ennature Bio Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Ennature Bio Pharma Ltd quarterly results
| ₹ crore | Sep 2025 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Sales | 54.14 | 90.39 | 78.46 |
| Expenses | 48.1 | 80.4 | 68.12 |
| Operating profit | 6.04 | 9.99 | 10.34 |
| OPM % | 11.16% | 11.05% | 13.18% |
| Other income | 0 | 0 | 0 |
| Interest | 3.79 | 0.04 | 0.03 |
| Depreciation | 3.61 | 3.7 | 3.7 |
| Profit before tax | -1.36 | 6.25 | 6.61 |
| Tax % | -5.88% | 25.44% | 26.17% |
| Net profit | -1.28 | 4.66 | 4.89 |
| EPS (₹) | -640.00 | 2,330.00 | 2.19 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ennature Bio Pharma Ltd annual results
| ₹ crore | Mar 2026 |
|---|---|
| Sales | 246 |
| Operating profit | 29 |
| OPM % | 12% |
| Net profit | 1 |
| EPS (₹) | 605.00 |
TTM is the trailing twelve months to the most recent quarter.
Ennature Bio Pharma Ltd balance sheet
| ₹ crore | Sep 2026 |
|---|---|
| Equity capital | 11 |
| Reserves | 521 |
| Borrowings | 0 |
| Other liabilities | 173 |
| Total liabilities | 705 |
| Fixed assets | 537 |
| CWIP | 11 |
| Investments | 0 |
| Other assets | 157 |
| Total assets | 705 |
As reported by the company. Total assets equal total liabilities by construction.
Ennature Bio Pharma Ltd shareholding pattern
| % held | Nov 2026 |
|---|---|
| Promoters | 59.63% |
| FIIs | 2.44% |
| DIIs | 4.61% |
| Public | 33.33% |
| No. of shareholders | 48,292 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Ennature Bio Pharma Ltd
Ennature Bio Pharma Ltd corporate filings
- Ennature Bio Pharma Limited receives CARE Ratings assignment of bank facilities: Long-term ₹50 crore at CARE A-; Stable and Short-term ₹50 crore at CARE A2+, total facilities ₹100 croreCompany Updatehigh impact
Cruxal's analysis: Ennature Bio Pharma Limited (the demerged entity of India Glycols Limited) disclosed that…
Read the full analysis - Ennature Bio Pharma Limited announces senior management appointments effective 12 November 2026Company Updatemedium impact
Cruxal's analysis: Ennature Bio Pharma Limited (demerged division of India Glycols) disclosed in a…
Read the full analysis - Regulatory update: Amendments to Memorandum & Articles of Association filed under Regulation 30 (LODR)Company Updatelow impact
Cruxal's analysis: Ennature Bio Pharma Ltd has filed an announcement under Regulation 30 (LODR) indicating…
Read the full analysis - Ennature Bio Pharma Limited reports Q2 FY2026 unaudited results with robust YoY revenue and turning profit; demerger scheme (biopharma arm vesting) becomes effective, signaling strategic realignment and potential re-ratingResulthigh impact
Cruxal's analysis: Ennature Bio Pharma Limited released unaudited standalone financial results for the…
Read the full analysis - Ennature Bio Pharma Limited schedules Board meeting to approve Q2 FY2027 unaudited results; no financials disclosed yetBoard Meetinglow impact
Cruxal's analysis: Ennature Bio Pharma Limited (scrip: ENNATURE) has issued a notice dated 05 November 2026…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find attached
Read the full analysis - Regulation 30 press release by Ennature Bio Pharma Ltd (545012) – attached media releaseCompany Updatelow impact
Cruxal's analysis: No numerical or operational details are provided in the text excerpt. The filing appears…
Read the full analysis
This page shows filings on a 24-hour delay. Subscribe to see them the moment they land, with Cruxal's analysis of what each one means. A free account sees them an hour after they land and tracks this company.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.